3298-98-4

Basic information

• Product Name: 2,3-bis(bromomethyl)-6,7-dimethylquinoxaline
• Synonyms: Quinoxaline, 2,3-bis(bromomethyl)-6,7-dimethyl-
• CAS NO: 3298-98-4
• Molecular Formula: C₁₂H₁₂Br₂N₂
• Molecular Weight: 344.0451
• Mol File: 3298-98-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 383°C at 760 mmHg
• Flash Point: 185.4°C
• Density: 1.707g/cm³
• Vapor Pressure: 9.98E-06mmHg at 25°C
• Refractive Index: 1.669
• CAS DataBase Reference: 2,3-bis(bromomethyl)-6,7-dimethylquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-bis(bromomethyl)-6,7-dimethylquinoxaline(3298-98-4)
• EPA Substance Registry System: 2,3-bis(bromomethyl)-6,7-dimethylquinoxaline(3298-98-4)

Safety Data

• Hazardous Substances Data: 3298-98-4(Hazardous Substances Data)

Usage

General Description

2,3-bis(bromomethyl)-6,7-dimethylquinoxaline is a chemical compound with the molecular formula C10H10Br2N2. It is a brominated quinoxaline derivative, which is commonly used as a precursor in the synthesis of various pharmaceuticals and agrochemicals. 2,3-bis(bromomethyl)-6,7-dimethylquinoxaline has been studied for its potential biological activities, including antimicrobial and antitumor properties. It is also utilized in the development of organic materials, such as conducting polymers and electronic devices. 2,3-bis(bromomethyl)-6,7-dimethylquinoxaline is an important building block in organic synthesis and has a wide range of applications in medicinal and materials chemistry.

Upstream product

• 3171-45-7 4,5-dimethyl-1,2-phenylenediamine 
• 6305-43-7 1,4-Dibromo-butane-2,3-dione 

Downstream Products

• 6957-19-3 2,3,6,7-tetramethylquinoxaline 
• 188292-23-1 6,7-Dimethyl-1,4-dihydro-2-oxa-3-thia-9,10-diaza-anthracene 3-oxide 

Relevant articles and documents

Simple charge transfer complexes of some new and of some known heterocyclic compounds of selenium and tellurium

Charge transfer (CT) complexes (1:1) of 2,5-dihydrotellurophene and the 3-methyl and 3,4-dimethyl compounds with TCNQ and tetrachlorobenzoquinone (TCB) are reported.The organotellurium compounds failed to give complexes with p-dinitrobenzene (DNB).The variation of solid state (disc) conductivity with temperature and as a function of methyl substituents is considered.The complexes show semi-conducting behaviour and a consideration of these data, together with IR and UV spectroscopic data, in comparison with those for 1,3-dihydro-2-telluraindene given the following order of donor power with respect to TCNQ: With respect to a given donor, the order of acceptor power os TCNQ > TCB > DNB. 1,3-Dihydro-2-selenaindene forms a complex with TCNQ.The molecular ionisation potential of the selenaindene is 7.4 eV (by mass spectroscopy) and it has been shown that the compound may be electrochemically oxidized to materials such as C8H8SePF6.New quinoxalino-1-chalcogenacyclopentanes are reported; namely those derived from selenium, and the 7,8-dimethyl series, those based on both selenium and tellurium.Their preparation and characterisation are described, and their chemistry shown to be strongly analogous to that of quinoxalino-1-telluracyclopentane.CT complexes of the new SeII and TeII compounds (1:1) are prepared with TCNQ which are believed to be strongly ionic.

Pharmacological investigation of quinoxaline-bisthiazoles as multitarget-directed ligands for the treatment of Alzheimer's disease

Alzheimer's disease (AD) is the most prevalent disease of old age leading to dementia. Complex AD pathogenesis involves multiple factors viz. amyloid plaque formation, neurofibrillary tangles and inflammation. Herein we report of a new series of quinoxaline-bisthiazoles as multitarget-directed ligands (MTDLs) targeting BACE-1 and inflammation concurrently. Virtual screening of a library of novel quinoxaline-bisthiazoles was performed by docking studies. The most active molecules from the docking library were taken up for synthesis and characterized by spectral data. Compounds 8a-8n showed BACE-1 inhibition in micro molar range. One of the compounds, 8n showed BACE-1 inhibition at IC50 of 3 ± 0.07 μM. Rat paw edema inhibition in acute and chronic models of inflammation were obtained at 69 ± 0.45% and 55 ± 0.7%, respectively. Compound 8n also showed noteworthy results in AlCl3 induced AD model. The treated rats exhibited excellent antiamnesic, antiamyloid, antioxidant, and neuroprotective properties. Behavioural parameters suggested improved cognitive functions which further validates the testimony of present study. Moreover, compound 8n was found to have inherent gastrointestinal safety. This new string of quinoxaline-bisthiazoles were identified as effective lead for the generation of potent MTDLs and compound 8n was found to showcase qualities to tackle AD pathogenesis.

Synthesis and antimicrobial activity of 2,3-bis(bromomethyl)quinoxaline derivatives

We synthesized 12 derivatives of 2,3-bis(bromomethyl)quinoxaline with substituents at the 6- and/or 7-positions, and evaluated their activities against bacteria and fungi. Of the 12 compounds, nine (1a-h, 1j, and 1k) showed antibacterial activity. The derivative 1g, which bears a trifluoromethyl group at the 6-position, showed the highest activity against Gram-positive bacteria, while 1c, which has a fluoro-group at the 6-position, showed the widest antifungal activity spectrum. However, only the derivative with an ethyl ester substitution, 1k showed activity against Gram-negative bacteria.